EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment

Beatriz E Jimenez Munarriz iD, Sam Khan iD, Yuchen Li iD, Nadia Ghazali iD, Geoffrey Liu

Cancer · 15.03.2025 · 131 (S1)

DOI: 10.1002/cncr.35786 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 02.04.2025. Verfasst von Beatriz E Jimenez Munarriz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, University Health Network-Princess Margaret Cancer Center, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer death worldwide. However, since the discovery and development of targeted therapies and immune checkpoint inhibitors, it has been a dramatically improved in survival outcomes and quality of life. Anaplastic lymphoma kinase ( ALK ) rearrangements occur in approximately 5% of patients with advanced non–small cell lung cancer (NSCLC), and the introduction of ALK tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm. Although head‐to‐head randomized controlled trials for late generation inhibitors are lacking, the authors will review the current available options, treatments efficacy, safety profiles, ALK mechanisms of resistance, as well as new promising treatments in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma KinaseLung NeoplasmsProtein Kinase InhibitorsHumansMolecular Targeted TherapyDrug Resistance, NeoplasmImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

ALK detectionALK diagnosisALK tyrosine kinase inhibitorslung cancer

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanProtein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Oncology Department, University Health Network-Princess Margaret Cancer Center, Toronto, Ontario, Canada.
  • Division of Medical oncology, Leicester Cancer Research, University of Leicester, Leicester, UK.
  • Department of Oncology, Queen's School of Medicine, Kingston, Ontario, Canada.
  • Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada.

ORCID-Profile: Beatriz E Jimenez Munarriz, Sam Khan, Yuchen Li, Nadia Ghazali

Zitieren

APA

Jimenez Munarriz, B. E., Khan, S., Li, Y., Ghazali, N., & Liu, G. (2025). Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment. Cancer, 131(S1). https://doi.org/10.1002/cncr.35786

Vancouver

Jimenez Munarriz BE, Khan S, Li Y, Ghazali N, Liu G. Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment. Cancer. 2025;131(S1). doi:10.1002/cncr.35786

BibTeX
@article{JimenezMunarriz2025,
  author = {Jimenez Munarriz, Beatriz E and Khan, Sam and Li, Yuchen and Ghazali, Nadia and Liu, Geoffrey},
  title = {Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {S1},
  doi = {10.1002/cncr.35786}
}
Kostenlos starten →